“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate and 95% disease-control rate.”

Checks out so far. 2 hold up so far.

0.9720 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 37% done · 25% counted in review coverage · 12% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.97, strongly supported · not yet reviewed by anyone else “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55%…” https://galedra.org/investigations/01a0ea6b-5407-7be6-bd7e-8138abdce093

“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen produced a 55% objective response rate.”

Supported · 0.9938 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

1 of 4 review checks done · 1 counted

See the evidence · Claim card

“In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.”

Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card